65.42
0.23%
+0.15
After Hours:
65.50
0.08
+0.12%
Overview
News
Price History
Option Chain
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences, Inc. stock is currently priced at $65.42, with a 24-hour trading volume of 12.21M.
It has seen a +0.23% increased in the last 24 hours and a -9.65% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $66.09 pivot point. If it approaches the $64.27 support level, significant changes may occur.
Previous Close:
$65.27
Open:
$65.5
24h Volume:
12.21M
Market Cap:
$81.58B
Revenue:
$27.12B
Net Income/Loss:
$5.66B
P/E Ratio:
15.04
EPS:
4.35
Net Cash Flow:
$7.42B
1W Performance:
-2.01%
1M Performance:
-9.65%
6M Performance:
-16.66%
1Y Performance:
-21.88%
Gilead Sciences, Inc. Stock (GILD) Company Profile
Name
Gilead Sciences, Inc.
Sector
Industry
Phone
650-574-3000
Address
333 Lakeside Drive, Foster City, CA
Gilead Sciences, Inc. Stock (GILD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-09-23 | Initiated | Deutsche Bank | Hold |
Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
Sep-06-23 | Initiated | HSBC Securities | Reduce |
Jul-24-23 | Reiterated | Barclays | Equal Weight |
May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Apr-28-23 | Resumed | Piper Sandler | Overweight |
Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Dec-13-22 | Resumed | BofA Securities | Neutral |
Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
Oct-28-22 | Reiterated | Cowen | Outperform |
Oct-28-22 | Reiterated | JP Morgan | Overweight |
Oct-28-22 | Reiterated | Jefferies | Buy |
Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
Oct-28-22 | Upgrade | Truist | Hold → Buy |
Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
May-23-22 | Initiated | SVB Leerink | Mkt Perform |
Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
Feb-02-22 | Reiterated | BofA Securities | Neutral |
Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
Feb-02-22 | Reiterated | Truist | Hold |
Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
Jan-28-22 | Upgrade | Argus | Hold → Buy |
Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
Dec-06-21 | Initiated | Goldman | Neutral |
Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Nov-19-21 | Resumed | Piper Sandler | Neutral |
Oct-20-21 | Resumed | Cowen | Outperform |
Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
Oct-28-20 | Initiated | UBS | Neutral |
Sep-30-20 | Resumed | Jefferies | Buy |
Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
Jul-31-20 | Reiterated | Credit Suisse | Neutral |
Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
Jul-31-20 | Reiterated | Piper Sandler | Overweight |
Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
Jul-31-20 | Reiterated | SunTrust | Hold |
Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
May-26-20 | Upgrade | SunTrust | Sell → Hold |
May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
May-01-20 | Downgrade | SunTrust | Hold → Sell |
Apr-27-20 | Downgrade | UBS | Buy → Neutral |
Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences, Inc. Stock (GILD) Latest News
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
Zacks Investment Research
Gilead Sciences (GILD) Q1 2024 Earnings Call Transcript
The Motley Fool
Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say
Zacks Investment Research
Gilead Sciences (GILD) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?
Benzinga
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
Benzinga
Gilead Sciences, Inc. Stock (GILD) Financials Data
Gilead Sciences, Inc. (GILD) Revenue 2024
GILD reported a revenue (TTM) of $27.11 billion for the quarter ending December 31, 2023, a -0.61% decline year-over-year.
Gilead Sciences, Inc. (GILD) Net Income 2024
GILD net income (TTM) was $5.66 billion for the quarter ending December 31, 2023, a +23.34% increase year-over-year.
Gilead Sciences, Inc. (GILD) Cash Flow 2024
GILD recorded a free cash flow (TTM) of $7.42 billion for the quarter ending December 31, 2023, a -11.06% decrease year-over-year.
Gilead Sciences, Inc. (GILD) Earnings per Share 2024
GILD earnings per share (TTM) was $4.50 for the quarter ending December 31, 2023, a +23.29% growth year-over-year.
Gilead Sciences, Inc. Stock (GILD) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
GILEAD SCIENCES, INC. | 10% Owner |
Apr 02 '24 |
Buy |
0.76 |
485,250 |
368,790 |
7,345,473 |
Parsey Merdad | Chief Medical Officer |
Apr 01 '24 |
Sale |
72.96 |
2,000 |
145,920 |
96,304 |
Parsey Merdad | Chief Medical Officer |
Feb 29 '24 |
Sale |
72.74 |
8,230 |
598,624 |
92,706 |
Parsey Merdad | Chief Medical Officer |
Feb 28 '24 |
Sale |
73.18 |
2,000 |
146,360 |
100,936 |
GILEAD SCIENCES, INC. | 10% Owner |
Feb 12 '24 |
Buy |
22.00 |
910,000 |
20,020,000 |
4,126,119 |
GILEAD SCIENCES, INC. | 10% Owner |
Jan 29 '24 |
Buy |
21.00 |
15,238,095 |
319,999,995 |
30,061,124 |
Dickinson Andrew D | Chief Financial Officer |
Jan 16 '24 |
Sale |
85.78 |
5,000 |
428,900 |
101,534 |
Mercier Johanna | Chief Commercial Officer |
Jan 09 '24 |
Sale |
85.23 |
8,242 |
702,466 |
82,729 |
Dickinson Andrew D | Chief Financial Officer |
Oct 17 '23 |
Sale |
80.00 |
5,000 |
400,017 |
104,003 |
Parsey Merdad | Chief Medical Officer |
Sep 12 '23 |
Sale |
76.99 |
1,501 |
115,562 |
70,130 |
About Gilead Sciences, Inc.
Gilead Sciences, Inc. discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Tango Therapeutics, Inc.; AELIX Therapeutics S.L.; and TARGET PharmaSolutions, Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Cap:
|
Volume (24h):